Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
TSHA
#1815
Taysha Gene Therapies, Inc. Common Stock
4.5
3
+0.44%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+0.44%
Variazione Mensile
-4.43%
Variazione di 6 mesi
+51.51%
Variazione Annuale
+177.91%
Chiusura Precedente
4.5
1
Open
4.5
3
Bid
Ask
Low
4.5
3
High
4.5
3
Volume
115
Mercati
Mercato Azionario Statunitense
Salute
TSHA
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
204.94 M
205 M
214.66 M
272.79 M
273.92 M
—
Valuation ratios
Enterprise value
254.25 M
215.62 M
181.79 M
317.4 M
598.37 M
1.31 B
Price to earnings ratio
5.91
-4.81
-4.09
-6.79
-9.91
-25.6
Price to sales ratio
35.12
51.93
49.49
77.07
140.37
318.86
Price to cash flow ratio
5.06
5.33
4.24
7.61
11.23
28.41
Price to book ratio
1.2
6.05
1.08
1.39
1.68
10.2
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.14
0.12
0.16
0.08
0.1
0.46
Return on equity %
0.29
0.26
0.39
0.11
0.15
0.91
Return on invested capital %
257.93
221.99
263.06
359.78
441.35
1 286.18
Gross margin %
100
100
100
100
—
—
Operating margin %
1 448.43
985.76
930.54
1 347.08
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 427.52
929.03
935.23
1 353.58
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
5.51
5.42
5.35
12.48
10.48
33.72
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.01
0.02
0.01
0
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.24
0.27
0.31
0.12
0.16
0.86
Long term debt to total equity ratio
0.48
0.61
0.77
0.17
0.23
1.78
Per share metrics
Operating cash flow per share
0.08
0.07
0.08
0.07
0.07
0.29
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
0.59
0.56
0.43
1.05
0.84
2.88
Net current asset value per share
0.6
0.57
0.45
1.06
0.85
2.93
Tangible book value per share
0.33
0.29
0.2
0.83
0.62
1.94
Working capital per share
0.49
0.46
0.36
0.98
0.77
2.57
Book value per share
0.33
0.29
0.2
0.83
0.62
1.94
Notizie
Dal laboratorio al rally: Wells Fargo seleziona i migliori titoli biotech SMID-Cap per il 2026
Stifel conferma il rating Buy sulle azioni Neurogene, cita margine di sicurezza
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Taysha doses first patient in pivotal Rett syndrome gene therapy trial
Il titolo di Autolus Therapeutics sale dopo l’aumento del target price di Needham
Il titolo di Taysha Gene Therapies tocca il massimo di 52 settimane a $5,98
Taysha Gene Therapies stock hits 52-week high at $5.98
Titoli Biotech: Jefferies nomina le sue 6 migliori scelte per il 2026
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026
Citizens conferma il rating Market Outperform per le azioni di Taysha Gene Therapies
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock
Il titolo di Taysha Gene Therapies raggiunge il massimo di 52 settimane a 5,51 USD